- Email: [email protected]
JP Air Tech commissions new filter media test rig
NEWS
De Nora opens new US$29mn plant in Ohio
D
e Nora has inaugurated a US$29 million greenfield electrode manufacturing facility in Mentor, Ohio, USA. The 110 000 sq ft energy- and water-efficient building has been designed for flexibility in production planning and will reduce lead time, optimise capacity and improve efficiency. “This key investment in the US is an important step for De Nora as we grow into our vision of being a premier partner to our water and wastewater customers worldwide,” said Dr Mirka Wilderer, De Nora Water Technologies CEO. “Our new facility in Ohio uses advanced technologies with low environmental impact and high energy efficiency with particular attention to the circular economy and the reduction of water consumption.” “In addition to needing a larger and technically more advanced plant that was in step with growth and business changes to benefit our customers, we also took the needs of our employees – the heart of our company – into consideration when choosing the location of the new plant,” said Frank Tomaselli, president and chief regional officer of De Nora Tech. “We are pleased that all 160 employees made the move from the Chardon plant – built 50 years ago – to the new state-of-the-art facility in Mentor.” The 18-acre site has space for further expansion. An additional process line has already been approved and is planned for implementation in the next two years, increasing the covered area by 17 000 sq ft. For further information, visit www.denora.com
De.mem completes placement with institutional investors
D
e.mem Ltd has received commitments for approximately A$2.95 million of new investment by a group of institutional and other investors through a placement of ordinary equity in the water and wastewater treatment company. The Singaporean-Australian company will issue 14.755 million new De.mem shares once the committed capital has all been received. 14
Filtration Industry Analyst
The additional capital has been raised in anticipation of new Build-Own-Operate (BOO) contract awards. Growing BOO revenues is an important part of De.mem’s strategy because of the recurring revenue stream through equipment rentals. De.mem may also use part of the additional capital raised for general working capital and to pursue other strategic growth initiatives. “The investment received from such a high-quality group of investors underlines the attractive investment proposition of De.mem. Each investor is known to be a long-term supporter of high-quality growth businesses,” said De.mem CEO Andreas Kroell. “The placement coincides with the rapid expansion and growth of De.mem’s business. We are focusing on growing our recurring revenues, diversifying our revenues across Australia and internationally, selectively advancing our proprietary product range and expanding into high growth customer verticals such as the food and beverage segment. This capital raising assists with advancement of these objectives.” For further information, visit www.demembranes.com
JP Air Tech commissions new filter media test rig
J
P Air Tech has begun the process of purchasing and installing new MFP Nano plus filter test rig equipment which will be used for filter media design, product development and quality control. Supplied by German company Palas, the MFP filter test rig is a modular filter testing system for flat filter media and small minifilters, which can quickly measure pressure loss curves and fractional separation efficiency. The MFP Nano plus has integrated mass flow controllers that it uses to control the volume flow and can be automatically monitored and controlled via the filter test software. The new test rig will operate according to DIN EN 1822-3 and ISO 29463-3, and comes with a powerful nano particle measuring device with a measurement range from 5 nm to 1 µm. It also allows the use of different test aerosols such as NaCl/KCl or DEHS, and provides a clear indication of the MPPS range. Jorgen Poulsen, managing director of JP Air Tech, said: “The filter media test rig will allow our engineers to conduct precise filter media testing.” For further information, visit www.jpairtech.com and www.palas.de
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) Limited 12976 The content of this newsletter is compiled from a variety of sources including press releases.
September 2019
De Nora opens new US$29mn plant in Ohio
D
e Nora has inaugurated a US$29 million greenfield electrode manufacturing facility in Mentor, Ohio, USA. The 110 000 sq ft energy- and water-efficient building has been designed for flexibility in production planning and will reduce lead time, optimise capacity and improve efficiency. “This key investment in the US is an important step for De Nora as we grow into our vision of being a premier partner to our water and wastewater customers worldwide,” said Dr Mirka Wilderer, De Nora Water Technologies CEO. “Our new facility in Ohio uses advanced technologies with low environmental impact and high energy efficiency with particular attention to the circular economy and the reduction of water consumption.” “In addition to needing a larger and technically more advanced plant that was in step with growth and business changes to benefit our customers, we also took the needs of our employees – the heart of our company – into consideration when choosing the location of the new plant,” said Frank Tomaselli, president and chief regional officer of De Nora Tech. “We are pleased that all 160 employees made the move from the Chardon plant – built 50 years ago – to the new state-of-the-art facility in Mentor.” The 18-acre site has space for further expansion. An additional process line has already been approved and is planned for implementation in the next two years, increasing the covered area by 17 000 sq ft. For further information, visit www.denora.com
De.mem completes placement with institutional investors
D
e.mem Ltd has received commitments for approximately A$2.95 million of new investment by a group of institutional and other investors through a placement of ordinary equity in the water and wastewater treatment company. The Singaporean-Australian company will issue 14.755 million new De.mem shares once the committed capital has all been received. 14
Filtration Industry Analyst
The additional capital has been raised in anticipation of new Build-Own-Operate (BOO) contract awards. Growing BOO revenues is an important part of De.mem’s strategy because of the recurring revenue stream through equipment rentals. De.mem may also use part of the additional capital raised for general working capital and to pursue other strategic growth initiatives. “The investment received from such a high-quality group of investors underlines the attractive investment proposition of De.mem. Each investor is known to be a long-term supporter of high-quality growth businesses,” said De.mem CEO Andreas Kroell. “The placement coincides with the rapid expansion and growth of De.mem’s business. We are focusing on growing our recurring revenues, diversifying our revenues across Australia and internationally, selectively advancing our proprietary product range and expanding into high growth customer verticals such as the food and beverage segment. This capital raising assists with advancement of these objectives.” For further information, visit www.demembranes.com
JP Air Tech commissions new filter media test rig
J
P Air Tech has begun the process of purchasing and installing new MFP Nano plus filter test rig equipment which will be used for filter media design, product development and quality control. Supplied by German company Palas, the MFP filter test rig is a modular filter testing system for flat filter media and small minifilters, which can quickly measure pressure loss curves and fractional separation efficiency. The MFP Nano plus has integrated mass flow controllers that it uses to control the volume flow and can be automatically monitored and controlled via the filter test software. The new test rig will operate according to DIN EN 1822-3 and ISO 29463-3, and comes with a powerful nano particle measuring device with a measurement range from 5 nm to 1 µm. It also allows the use of different test aerosols such as NaCl/KCl or DEHS, and provides a clear indication of the MPPS range. Jorgen Poulsen, managing director of JP Air Tech, said: “The filter media test rig will allow our engineers to conduct precise filter media testing.” For further information, visit www.jpairtech.com and www.palas.de
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) Limited 12976 The content of this newsletter is compiled from a variety of sources including press releases.
September 2019